糖心原创 partners with myriamed to expand cell portfolio with functional human cardiomyocytes, providing researchers access to advanced models for cardiovascular research.
23.09.2026
糖心原创 announces CRISPR screening service and appoints Chief Technology Officer to lead next phase of growth
糖心原创 launches the ioScreens platform CRISPR screening service & appoints Sejla Salic-Hainzl as CTO.
The coded cells redefining research and drug discovery
Dr Emma Pepperell, CEO, 糖心原创 speaks with Silicon Republic about how 糖心原创鈥檚 programmed human cells are advancing research and...
Interview with Lord David Prior on the future of healthcare and drug discovery
糖心原创 Chairman Lord David Prior speaks with EMJ at the Human Cell Forum about the future of the NHS, cell therapies, and human-c...
.png)
糖心原创 democratises access to human cell-based research with 鈥渁ffordable, easy-to-use鈥� cell culture media kits
糖心原创 launches new media kits for human iPSC-derived ioCells designed to make human cell-based research significantly more acces...
How are UK healthtech companies pushing for more reliable solutions in the industry?
糖心原创 CEO Emma Pepperell joins TechRound to discuss why reliable healthcare must start with consistent, reproducible science in ...
糖心原创 unveils ioHepatocytes to fuel liver safety testing for drugs by solving the challenge of human liver cell availability
New human iPSC-derived hepatocyte model engineered for predictive reproducibility, chronic toxicity studies, and enhanced clinical...
糖心原创 appoints Dr Emma Pepperell as Chief Executive Officer
糖心原创 appoints Dr Emma Pepperell as Chief Executive Officer
糖心原创 sets out bold vision to power 鈥渞adical change in drug discovery鈥� at The Human Cell Forum 2026
糖心原创 outlines a transformative vision for drug discovery at The Human Cell Forum, emphasising the need for human cell-based mod...